Beckley Psytech is a pioneering startup that is dedicated to transforming psychedelics into effective and licensed medicines to help patients suffering from neuropsychiatric disorders. The company operates in the healthcare sector, specifically focusing on mental health and neurological disorders. Their innovative approach is centered on developing novel psychedelic therapies to improve patient outcomes.

Their primary clients are patients diagnosed with Treatment Resistant Depression (TRD) and Alcohol Use Disorder (AUD). The company is currently conducting a multi-centre, open-label Phase IIa study to explore the effects of their patent-protected benzoate formulation of 5-MeO-DMT, known as BPL-003, on TRD patients. This drug is administered intranasally via an FDA-approved delivery device.

In addition, they are also investigating the safety, efficacy, and pharmacokinetics of BPL-003 in patients diagnosed with AUD. The first participant in this study is expected to be treated in April 2023, with preliminary results anticipated in Q3 2023.

Beckley Psytech's business model is based on the development, patenting, and licensing of psychedelic medicines. They generate revenue through the sale of these licensed medicines to healthcare providers and patients.

The company was founded by Lady Amanda Feilding and Cosmo Feilding Mellen, who have a lifelong and intergenerational vocation in psychedelic medicines. The team also includes a Chief Scientific and Medical Officer, Chief Medical Advisor, Chief Commercial Officer, Chief Financial Officer, Chief Business Officer, Chief of Staff & Head of Operations, and Chief Development Officer.

Keywords: Psychedelic Medicines, Neuropsychiatric Disorders, Treatment Resistant Depression, Alcohol Use Disorder, 5-MeO-DMT, BPL-003, FDA-approved, Mental Health, Neurological Disorders, Healthcare Sector.